<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03626233</url>
  </required_header>
  <id_info>
    <org_study_id>CPVP</org_study_id>
    <nct_id>NCT03626233</nct_id>
  </id_info>
  <brief_title>Study of the Physiology of Pre-eclampsia and Vascular IUGR With Constitution of a Biological Collection</brief_title>
  <acronym>CPVP</acronym>
  <official_title>Study of the Physiology of Pre-eclampsia and Vascular Intrauterine Growth Restriction With Constitution of a Biological Collection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preeclampsia and intrauterine growth retardation (IUGR) are serious and frequent pathologies,
      specific to pregnancy. They represent 70 000 new cases a year, or 9% of pregnancies and cause
      50,000 premature births per year in France. The consequences in terms of morbidity and
      perinatal morbidity and the medical and economic costs make it an issue public health.
      Pre-eclampsia associates maternal hypertension with dysfunction kidney. There is no cure for
      pre-eclampsia or IUGR vascular during pregnancy. These pathologies invariably evolve towards
      a maternal and / or fetal aggravation sometimes very fast. Primary prevention and secondary
      education and screening for these pathologies are still insufficient. A better understanding
      of the pathophysiology of these placental vascular pathologies is necessary for the
      development of supported medical, obstetric and pediatric that will improve the state of
      health maternal and neonatal
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2018</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>genomic analysis on placenta</measure>
    <time_frame>day of delivery</time_frame>
    <description>by chromatin immunoprecipitation-sequencing (ChIP-seq)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>genomic analysis on blood</measure>
    <time_frame>day of delivery</time_frame>
    <description>by ChIP-seq</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>genomic analysis on placenta</measure>
    <time_frame>day of delivery</time_frame>
    <description>by immunohistochemistry an polymerase chain-reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VEGF blood level</measure>
    <time_frame>day of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PLGF blood level</measure>
    <time_frame>day of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sFlt1 blood level</measure>
    <time_frame>day of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sKDR blood level</measure>
    <time_frame>day of delivery</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>Vascular group</arm_group_label>
    <description>Pregnant women with vascular pathology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Pregnancy without any vascular complication
Delivery before or after 37 weeks of gestation (GW)
In case of delivery after 37GW: birth by cesarean delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>collect of placenta, blood and urinary samples at delivery</intervention_name>
    <description>collect of placenta, blood and urinary samples at delivery</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Vascular group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for maternal DNA sequencing and angiogenic factors (VEGF, PLGF, sFLt-1, sQDR)
      Urinary samples: Angiogenic factors Placenta: for placenta DNA sequencing and angiogenic
      factors
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        pregnant women with or without vascular pathology
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant women

          -  With or without vascular pathology

        Exclusion Criteria:

          -  refusal to participate

          -  multiple pregnancy

          -  major fetal malformation diagnosed during pregnancy follow-up
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edouard Lecarpentier, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHI Creteil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane REDEL</last_name>
    <phone>145175530</phone>
    <phone_ext>0033</phone_ext>
    <email>diane.redel@chicreteil.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>camille Jung</last_name>
    <phone>157022268</phone>
    <phone_ext>0033</phone_ext>
    <email>camille.jung@chicreteil.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHi Creteil</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane REDEL</last_name>
      <phone>145175530</phone>
      <phone_ext>0033</phone_ext>
      <email>diane.redel@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Edouard LECARPENTIER, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

